

Wessex Regional Genetics Laboratory Publications 2019

Araf S, Wang J, Ashton-Key M, Korfi K, Di Bella D, Rio-Machin A, Odabashian M, Foria V, Du M-Q, Cucco F, Barrans S, Johnson P, **Laird SR, Fisher AM**, Cullis JO, Graham TA, Okosun J, Fitzgibbon J, **Chiecchio L**. Case report: Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant. *Haematologica* 2019 **104**: e174-e177

Brightman DS, Lokulo-Sodipe O, Searle BA, **Mackay DJG**, Davies JH, Temple IK, Dauber A. Growth hormone improves short-term growth in patients with Temple syndrome. *Horm. Res. Paediatr.* 2018 **90** (6): 407-413 (release date April 2019).

Broderick V, **Waghorn K**, Langabeer SE, Jeffers M, **Cross NCP**, Hayden PJ. Letter to the Editor: Molecular response to imatinib in *KIT* F522C-mutated systemic mastocytosis. *Leuk. Research* 2019 **77**: 28-29

Bunyan DJ, Thomas NS. Screening of a large cohort of blepharophimosis, ptosis, and epicanthus inversus syndrome patients reveals a very strong paternal inheritance bias and a wide spectrum of *FOXL2* mutations. *Eur. J. Med. Genet.* 2019 **62** (7): id103668

Chase A, Pellagatti A, Singh S, **Score J**, Tapper WJ, **Lin F, Hoade Y, Bryant C**, Trim N, Yip BH, Zoi K, Rasi C, Forsberg LA, Dumanski JP, Boultonwood J, **Cross NCP**. *PRR14L* mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasia. *Leukemia* 2019 **33**: 1184-1194

Cross NCP, Hoade Y, Tapper WJ, Carreno-Tarragona G, Fanelli T, Jawhar M, Naumann N, Pieniak I, Lübke J, Ali S, Bhuller K, Burgstaller S, Cargo C, Cavenagh J, Duncombe AS, Das-Gupta E, Evans P, Forsyth P, George P, Grimley C, Jack F, Munro L, Mehra V, Patel K, Rismani A, Sciuccati G, Thomas-Dewing R, Thornton P, Virchis A, Watt S, Wallis L, Whiteway A, Zegocki K, Bain BJ, Reiter A, **Chase A**. Recurrent activating *STAT5B* N642H mutation in myeloid neoplasms with eosinophilia. *Leukemia* 2019 **33**: 415-425

Gheldhof A, **Mackay DJG**, Cheong Y, Verpoest W. Genetic diagnosis of subfertility: the impact of meiosis and maternal effects. *J. Med. Genet.* 2019 **56**: 271-282

Goodison N, **Mackay DJG**, Temple IK. Genetics, molar pregnancies and medieval ideas of monstrous births: the lump of flesh in *The King of Tars*. *Med. Humanit.* 2019 **45** (1): doi:10.1136/medhum-2017-011387

Jawhar M, Döhner K, Kreil S, Schwaab J, Shoumariyeh K, Meggendorfer M, Span LLF, Fuhrmann S, Naumann N, Horny HP, Sotlar K, Kubuschok B, von Bubnoff N, Spiekermann K, Heuser M, Metzgeroth G, Fabarius A, Klein S, Hofmann WK, Kluin-Nelemans HC, Haferlach T, Döhner H, **Cross NCP**, Sperr WR, Valent P, Reiter A. *KIT* D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. *Leukemia* 2019 **33**: 1124-1134

Jawhar M, Schwaab J, Álvarez-Twose I, Shoumariyeh K, Naumann N, Lübke J, Perkins C, Muñoz-González JI, Meggendorfer M, Kennedy V, Metzgeroth G, Fabarius A, Pfeifer D, Sotlar K, Horny HP, von Bubnoff N, Haferlach T, **Cross NCP**, Hofmann WK, Sperr WR, García-Montero AC, Valent P, Gotlib J, Orfao A, Reiter A. MARS: Mutation-Adjusted Risk Score for advanced systemic mastocytosis. *J. Clin. Oncol.* 2019 **37** (31): 2846-2856

Jeffries AR, Maroofian R, Salter CG, Chioza BA, Cross HE, Patton MA, Dempster E, Temple IK, **Mackay DJG**, Rezwan FI, Aksglaede L, Baralle D, Dabir T, Hunter MF, Kamath A, Kumar A, Newbury-Ecob R, Selicorni A, Springer A, Van Maldergem L, Varghese V, Yachelevich N, Tatton-Brown K, Mill J, Crosby AH, Baple EL. Growth disrupting mutations in epigenetic regulatory molecules are associated with abnormalities of epigenetic aging. *Genome Res.* 2019 **29**: 1057-1066

Krzyzewska IM, Alders M, Maas SM, Blik J, Venema A, Henneman P, Rezwan FI, v. d. Lip K, Mul AN, **Mackay DJG**, Mannens MMAM. Genome-wide methylation profiling of Beckwith-Wiedemann syndrome patients without molecular confirmation after routine diagnostics. *Clin. Epigenetics* 2019 **11**: 53

Lemež P, Dignum H, Ganczakowski M, **Chiecchio L**, Ayto R, **Baker K**, Singh S, Cranfield T, Matthias G, James C, Corser R. Prolonged survival of a 79-year-old man with acute myeloid leukemia M2, normal karyotype, *NPM1* and *FLT3-ITD* mutations, WBC $33.7 \times 10^9/L$, and involving only granulocyte-macrophage line on 53 cycles of low-dose cytarabine. *Ann. Hematol. Oncol.* 2019 **6** (11): id1276.

Levavi H, Tripodi J, Marcellino B, Mascarenhas J, Jones AV, **Cross NCP**, Gruenstein D, Najfeld V. A novel t(1;9)(p36;p24.1) *JAK2* translocation and review of the literature. *Acta Haematol.* 2019 **142**: 105-112

Lord J, McMullan DJ, Eberhardt RY, Rinck G, Hamilton SJ, Quinlan-Jones E, Prigmore E, Keelagher R, Best SK, Carey GK, Mellis R, Robart S, Berry IR, Chandler KE, Cilliers D, Cresswell L, Edwards SL, Gardiner C, Henderson A, Holden ST, Homfray T, Lester T, Lewis RA, Newbury-Ecob R, Prescott K, Quarrell OW, Ramsden SC, Roberts E, Tapon D, Tooley MJ, Vasudevan PC, Weber AP, Wellesley DG, Westwood P, **White H**, Parker M, Williams D, Jenkins L, Scott RH, Kilby MD, Chitty LS, Hurles ME, Maher ER. Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study. *Lancet* 2019 **393**: 747-757.

Lübke J, Naumann N, Kluger S, Schwaab J, Metzgeroth G, Evans E, Gardino AK, Lengauer C, Hofmann WK, Fabarius A, **Cross NCP**, Reiter A, Jawhar M. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with *KIT* D816V positive advanced systemic mastocytosis. *Leukemia* 2019 **33**: 1195-1205.

Mackay DJG, Blik J, Lombardi MP, Russo S, Calzari L, Guzzetti S, Izzi C, Selicorni A, Melis D, Temple K, Maher E, Brioude F, Netchine I, Eggermann T. Discrepant molecular and clinical diagnoses in Beckwith-Wiedemann and Silver-Russell syndromes. *Genetics Research* **101**: e3, 1-5.

Möbius S, Schenk T, Himsel D, Maier J, Franke G-N, Saussele S, Pott C, Andrikovics H, Meggyesi N, Machova-Polakova K, Zizkova H, Jurcek T, Mesanovic S, Zadro R, Gottardi E, Haenig J, Schuld P, **Cross NCP**, Hochhaus A, Ernst T. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). *J. Cancer Res. Clin. Oncol.* 2019 **145**: 1645-1650

Monk D, **Mackay DJG**, Eggermann T, Maher ER, Riccio A. Genomic imprinting disorders: lessons on how genome, epigenome and environment interact. *Nat. Rev. Genet.* 2019 **20**: 235-248

Nolin SL, Glicksman A, Tortora N, Allen E, **Macpherson J**, Mila M, Vianna-Morgante AM, Sherman SL, Dobkin C, Latham GJ, Hadd AG. Expansions and contractions of the *FMR1* CGG repeat in 5,508 transmissions of normal, intermediate, and premutation alleles. *Am. J. Med. Genet.* 2019 **179A**: 1148-1156.

O’Gorman L, Cree AJ, **Ward D**, Griffiths HL, Sood R, Denniston AK, Self JE, Ennis S, Lotery AJ, Gibson J. Comprehensive sequencing of the myocilin gene in a selected cohort of severe primary open-angle glaucoma patients. *Scientific Reports* 2019 **9**: id3100

O’Gorman L, Norman CS, Michaels L, Newall T, Crosby AH, **Mattocks C**, Cree AJ, Lotery AJ, Baple EL, Ratnayaka JA, Baralle D, Lee H, Osborne D, Shawkat F, Gibson J, Ennis S, Self JE. A small gene sequencing panel realises a high diagnostic rate in patients with congenital nystagmus following basic phenotyping. *Scientific Reports* 2019 **9**: id13229.

O’Sullivan JM, Hamblin A, Yap C, Fox S, Boucher R, Panchal A, Alimam S, Dreau H, Howard K, Ware P, **Cross NCP**, McMullin MF, Harrison CN, Mead AJ. The poor outcome in high molecular risk, hydroxycarbamide resistant/intolerant ET is not ameliorated by ruxolitinib. *Blood* 2019 **134** (23): 2107-2111

Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, **Salmon M**, Gleich GJ, **Cross NCP**, Constantinescu SN, O’Hare T, Prchal JT, Deininger MW. *JAK2^{ex13InDel}* drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. *Blood* 2019 **134** (26): 2388-2398

Schoemaker MJ, Jones ME, Higgins CD, Wright AF, **United Kingdom Clinical Cytogenetics Group**, Swerdlow AJ. Mortality and cancer incidence in carriers of balanced Robertsonian translocations: a national cohort study. *Am. J. Epidemiol.* 2019 **188** (3): 500-508

Schoemaker MJ, Jones ME, Higgins CD, Wright AF, **UK Clinical Cytogenetics Group**, Swerdlow AJ. Mortality and cancer incidence in carriers of constitutional t(11:22)(q23;q11) translocations: a prospective study. *Int. J. Cancer* 2019 **145** (6): 1493-1498.

Sparago A, Verma A, Patricelli MG, Pignata L, Russo S, Calzari L, De Francesco N, Del Prete R, Palumbo O, Carella M, **Mackay DJG**, Rezwani FI, Angelini C, Cerrato F, Cubellis MV, Riccio A. The phenotypic variations of multi-locus imprinting disturbances associated with maternal-effect variants of *NLRP5* range from overt imprinting disorder to apparently healthy phenotype. *Clin. Epigenetics* 2019 **11**: 190